SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Humanm Antibodys:ABGX,MEDX, CAT , Morphosys....

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mel Spivak who wrote (4)3/10/2000 8:03:00 AM
From: Mel Spivak   of 23
 
MEDX in a new collaboration w REGN:

Medarex, Regeneron to co-develop, market new drugs

PRINCETON, N.J., March 10 (Reuters) - Medarex Inc. (NasdaqNM:MEDX - news) and
Regeneron Pharmaceuticals Inc. (NasdaqNM:REGN - news) have formed an alliance to
develop and market drugs based on antibodies, the natural disease fighters made by the
body's immune system, Medarex said on Friday.

The companies have selected more than 20 initial targets, including growth factors, and anticipate adding more targets in the
future.

The companies will share preclinical and clinical responsibilities and will jointly market any drugs that result from the strategic
alliance, Medarex said in a statement.

Further details of the collaboration were not immediately available.

Medarex uses a technology that produces large quantities of an antibody that binds very selectively with a foreign invader.
Regeneron has developed potential new treatments for some of the most serious and widespread disease and conditions,
including cancer, asthma, arthritis and vascular disease.

Medarex shares closed on Thursday at 166-41/32. Regeneron closed at 41-9/16
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext